Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes
- PMID: 32134429
- DOI: 10.1001/jamaoncol.2020.0065
Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes
Comment in
-
Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes-Reply.JAMA Oncol. 2020 Apr 1;6(4):590. doi: 10.1001/jamaoncol.2020.0068. JAMA Oncol. 2020. PMID: 32134432 No abstract available.
Comment on
-
Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.JAMA Oncol. 2019 Oct 1;5(10):1504-1506. doi: 10.1001/jamaoncol.2019.2963. JAMA Oncol. 2019. PMID: 31415061 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical